Dr. Céline Vallot

Dr. Céline Vallot, Principal Investigator of the "Dynamics of epigenetics plasticity in cancer" group at the Curie Institute, Paris, France, will present the lecture "Tracking the dynamics of chromatin states in tumor cells at single-cell resolution: response and resistance to cancer therapies."

Meet the speaker

If you want to meet Dr. Céline Vallot on Jan. 24th or Jan. 25th, please book a time slot at https://doodle.com/poll/fb2y2qhmimm26p3e and send an email to anthony.mathelier@ncmm.uio.no.

Abstract

The dynamic nature of chromatin and transcriptional features are expected to participate in tumor evolution, particularly in the context of response to cancer treatment and acquisition of resistance. Yet, the contribution of epigenetic plasticity to cancer cells remains unclear and means to target it are still rather non-specific and inefficient, mostly due to the lack of relevant cellular models and in vivo datasets. We have recently achieved the mapping of histone marks at single-cell resolution in human breast tumors, enabling the investigation of the dynamics of chromatin marks, and its contribution to tumor evolution. Using in vivo models of acquired resistance to cancer treatment, our recent data indicate that resistance to tamoxifen or chemotherapy may be associated with the emergence of an epigenetic subclone, characterized by a specific histone mark profile that could be stable along cell generations. More generally, the research projects of the group aim for a better understanding of the mechanisms of non-genetic selection, with the objective to design strategies to enhance or restore sensitivity to cancer treatments.

Website

https://science.institut-curie.org/research/biology-cancer-genetics-and-epigenetics/umr3244-dynamics-of-genetic-information/team-vallot/

Junior talk

Dr. Aziz Khan , postdoctoral fellow in the Computational Biology & Gene Regulation group at NCMM, UiO, and eLife embassador, will talk about "Preprints in the life sciences."

Published Aug. 13, 2019 11:08 AM - Last modified Aug. 13, 2019 11:09 AM